NEW YORK (GenomeWeb News) – Lucigen and Research Corporation Technologies on Wednesday announced a commercialization and distribution partnership for the first Escherichia coli-based recombinant system without endotoxin.

The CleanColi Expression System is for protein expression and contains a genetically modified lipopolysaccharide that does not create an endotoxic response in human cells. Because of this, researchers will be able to increase their productivity since they will no longer need to remove unwanted endoxin, Lucigen and RCT said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.